Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...

The cost of Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can vary based on several factors, including your insurance coverage. Coupons and drug savings ...

Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) is a prescription drug used to treat COPD. With COPD, you have lung damage that worsens over time ...

Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) can cause side effects that range from mild to serious. More common side effects include headache and ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...

(Reuters) - GlaxoSmithKline Plc said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler delivering three drugs at once ...

Some people with asthma need to use multiple inhaled medicines each day to keep their symptoms under control. The approval of long-acting, combination inhalers that contain more than one medicine is ...

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US New asthma indication for Trelegy Ellipta introduces an important ...

GlaxoSmithKline is spinning the first DTC campaign this week for its crucial new COPD drug, Trelegy Ellipta, backed by a throwback soundtrack. The theme song reworks The Jackson 5’s hit tune “ABC," ...

GlaxoSmithKline has seized the initiative with its three-drug COPD inhaler Trelegy Ellipta despite some new competition from AstraZeneca. To cement its lead, GSK is looking for a first-of-its-kind ...

GlaxoSmithKline plcGSK and partner Innoviva, Inc. INVA announced the approval of label expansion of chronic obstructive pulmonary disease ("COPD") drug, Trelegy Ellipta, in Europe. The drug is now ...

LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...